H. Moessler

发表

Neurotrophic effects of Cerebrolysin in the Mecp2308/Y transgenic model of Rett syndrome

E. Masliah, E. Rockenstein, L. Crews, 2008, Acta Neuropathologica.

Neuropeptide Treatment with Cerebrolysin Enhances the Survival of Grafted Neural Stem Cell in an α-Synuclein Transgenic Model of Parkinson’s Disease

E. Masliah, E. Rockenstein, Paula Desplats, 2015, Journal of experimental neuroscience.

Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials

W. Heiss, A. Guekht, D. Muresanu, 2017, Neurological Sciences.

Regional comparison of the neurogenic effects of CNTF-derived peptides and cerebrolysin in AβPP transgenic mice.

E. Masliah, E. Rockenstein, I. Grundke‐Iqbal, 2011, Journal of Alzheimer's disease : JAD.

Clinical Trial Protocols

M. Brainin, W. Heiss, N. Bornstein, 2022 .

Cerebrolysin enhances functional recovery following focal cerebral infarction in rats.

S. Finklestein, H. Moessler, Jingmei Ren, 2007, Restorative neurology and neuroscience.

Neuroprotection of Cerebrolysin in tissue culture models of brain ischemia: post lesion application indicates a wide therapeutic window

B. Hutter-Paier, M. Windisch, E. Doppler, 2006, Journal of Neural Transmission.

A peptide preparation protects cells in organotypic brain slices against cell death after glutamate intoxication

B. Hutter-Paier, M. Windisch, E. Doppler, 2005, Journal of Neural Transmission.

Positive effects of Cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study

V. Couceiro, L. Fernández-Novoa, R. Cacabelos, 2003, International clinical psychopharmacology.

Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil.

V. Couceiro, R. Cacabelos, C. Sampedro, 2011, Current Alzheimer research.

Serum VEGF Predicts Clinical Improvement Induced by Cerebrolysin Plus Donepezil in Patients With Advanced Alzheimer’s Disease

D. Muresanu, M. Fantini, H. Moessler, 2020, The international journal of neuropsychopharmacology.

Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure

E. Masliah, E. Rockenstein, A. Adame, 2014, BMC Neuroscience.

Cerebrolysin adjuvant treatment in Broca's aphasics following first acute ischemic stroke of the left middle cerebral artery

M. Serpe, D. Mureşanu, O. Bajenaru, 2010, Journal of medicine and life.

Efficacy and safety of Cerebrolysin in patients with hemorrhagic stroke

D. Mureşanu, C. Tiu, H. Moessler, 2010, Journal of medicine and life.

Effects of Cerebrolysin on amyloid-beta deposition in a transgenic model of Alzheimer's disease.

E. Masliah, M. Mallory, E. Rockenstein, 2002, Journal of neural transmission. Supplementum.

Cerebrolysin protects PC12 cells from CoCl2-induced hypoxia employing GSK3β signaling

S. Couillard-Després, L. Aigner, D. Meier, 2014, International Journal of Developmental Neuroscience.

Reduced TNF-α and increased IGF-I levels in the serum of Alzheimer's disease patients treated with the neurotrophic agent cerebrolysin.

R. Cacabelos, C. Sampedro, H. Moessler, 2009, The international journal of neuropsychopharmacology.

Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of Cerebrolysin

E. Masliah, E. Rockenstein, L. Crews, 2009, Acta Neuropathologica.

Treatment of Alzheimer's disease: A randomized, double-blind, placebo-controlled trial with a neurotrophic agent

M. Panisset, S. Gauthier, M. Windisch, 2000, Neurobiology of Aging.

A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial

W. Heiss, A. Guekht, C. Popescu, 2015 .

Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer’s disease with the neurotrophic compound Cerebrolysin™

E. Masliah, G. Larrea, E. Rockenstein, 2005, Journal of Neural Transmission.

Cerebrolysin decreases amyloid‐β production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease

E. Masliah, E. Rockenstein, L. Crews, 2006, Journal of neuroscience research.

A 24‐week, double‐blind, placebo‐controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease

D. Muresanu, V. Couceiro, L. Fernández-Novoa, 2006, European journal of neurology.

The SM 22 promoter directs tissue-specific expression in arterial but not in venous or visceral smooth muscle cells in transgenic mice.

J. Small, D. Paulin, S. Nagl, 1996, Development.

Nanodelivery of Cerebrolysin and Rearing in Enriched Environment Induce Neuroprotective Effects in a Preclinical Rat Model of Parkinson’s Disease

J. Lafuente, H. Sharma, L. Ugedo, 2017, Molecular Neurobiology.

Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer’s disease: results of a randomized, double‐blind, controlled trial investigating three dosages of Cerebrolysin

R. Cacabelos, C. Sampedro, E. Doppler, 2011, European journal of neurology.

Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial.

A. Guekht, H. Moessler, P. Novak, 2011, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

Effects of Cerebrolysin™ on neurogenesis in an APP transgenic model of Alzheimer’s disease

E. Masliah, E. Rockenstein, L. Crews, 2007, Acta Neuropathologica.

Apathy and APOE4 are associated with reduced BDNF levels in Alzheimer's disease.

E. Masliah, H. Moessler, A. Álvarez, 2014, Journal of Alzheimer's disease : JAD.

Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: Results of a 3-month extension study

A. Buzoianu, D. Muresanu, B. Popescu, 2010, Journal of the Neurological Sciences.

A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: Cognitive improvement correlates with qEEG acceleration

D. Muresanu, F. Moldovan, B. Popescu, 2008, Journal of the Neurological Sciences.

The neuroprotective effects of Cerebrolysin™ in a transgenic model of Alzheimer’s disease are associated with improved behavioral performance

E. Masliah, E. Rockenstein, A. Adame, 2003, Journal of Neural Transmission.

Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure

E. Masliah, E. Rockenstein, A. Adame, 2014, BMC Neuroscience.

Cerebrolysin modulates pronerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer's disease

E. Masliah, E. Rockenstein, A. Adame, 2013, Journal of neuroscience research.

Beneficial effects of a neurotrophic peptidergic mixture persist for a prolonged period following treatment interruption in a transgenic model of Alzheimer's disease

E. Masliah, E. Rockenstein, A. Adame, 2011, Journal of neuroscience research.

A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease.

M. Chesselet, E. Masliah, I. Tsigelny, 2016, Brain : a journal of neurology.

N-PEP-12 – a novel peptide compound that protects cortical neurons in culture against different age and disease associated lesions

B. Hutter-Paier, M. Windisch, E. Doppler, 2005, Journal of Neural Transmission.

D. Muresanu, H. Moessler, X. A. Alvarez, 2018, Journal of Alzheimer's disease : JAD.

Effects of N-PEP-12 on memory among older adults

S. Ferris, T. Crook, H. Moessler, 2005, International clinical psychopharmacology.

Neuroprotective treatment with Cerebrolysin in patients with acute stroke: a randomised controlled trial

G. Ladurner, G. Ladurner, H. Moessler, 2005, Journal of Neural Transmission.

A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease

S. Kasper, J. Spatt, H. Moessler, 2001, International clinical psychopharmacology.

Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent

S. Gauthier, M. Panisset, A. T. N. Group, 2002, Journal of Neural Transmission.

Sustained improvement of cognition and global function in patients with moderately severe Alzheimer's disease: a double-blind, placebo-controlled study with the neurotrophic agent Cerebrolysin.

H. Moessler, X. A. Alvarez, M. Rainer, 2002, Journal of neural transmission. Supplementum.

Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin.

D. Muresanu, H. Moessler, M. Rainer, 2002, Journal of neural transmission. Supplementum.

Long-term treatment of aged Long Evans rats with a dietary supplement containing neuroprotective peptides (N-PEP-12) to prevent brain aging: effects of three months daily treatment by oral gavage

B. Hutter-Paier, E. Doppler, H. Moessler, 2015, Journal of medicine and life.

Nano Drug delivery by Single-wall carbon nanotubes (SWCNTs) in the Central nervous system induces neurotoxicity. Potential neuroprotective effects of Cerebrolysin

D. Muresanu, A. Sharma, H. Sharma, 2014 .

Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate–severe traumatic brain injury

D. Muresanu, I. Tellado, R. Cacabelos, 2008, Journal of Neural Transmission.

Cerebrolysin and Recovery After Stroke (CARS)

W. Heiss, A. Guekht, C. Popescu, 2015, Stroke.

Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study.

V. Couceiro, L. Fernández-Novoa, R. Cacabelos, 2003 .

Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial

J. Vester, D. Mureşanu, H. Moessler, 2017, Journal of medicine and life.

[The effect of cerebrolysin in dosage 50 ml on the volume of lesion in ischemic stroke].

V. I. Skvortsova, H. Moessler, P. Novak, 2010, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

Synergistic Increase of Serum BDNF in Alzheimer Patients Treated with Cerebrolysin and Donepezil: Association with Cognitive Improvement in ApoE4 Cases

E. Masliah, D. Muresanu, J. Marey, 2016, The international journal of neuropsychopharmacology.

CEREBROLYSIN AND COMBINATION THERAPY ENHANCE SERUM BDNF IN AD PATIENTS

D. Muresanu, H. Moessler, Jesús Figueroa, 2014, Alzheimer's & Dementia.

Nanodelivery of Cerebrolysin as adjunct therapy with Functionalized magnetic iron oxide nanoparticles enhances neuroprotection

D. Muresanu, H. Sharma, H. Moessler, 2014 .

Apathy and APOE4 are associated with reduced BDNF levels in Alzheimer's disease.

E. Masliah, H. Moessler, M. Aleixandre, 2014, Journal of Alzheimer's disease : JAD.

C-REGS 2 - Design and methodology of a high-quality comparative effectiveness observational trial

M. Brainin, W. Heiss, N. Bornstein, 2021, Journal of Medicine and Life.

P2–402: Double–blind, placebo–controlled study of three different dosages of cerebrolysin in patients with mild to moderate Alzheimer's disease

R. Cacabelos, H. Moessler, M. Laredo, 2006 .